During Q4 2018 the big money sentiment decreased to 1. That’s change of Infinity, from 2018Q3’s Infinity. 2 investors sold all, 3 reduced holdings as Biomerica, Inc. ratio dived. 0 rose holdings while 5 funds acquired holdings. Funds hold 87,576 shares thus 72.23% less from 2018Q3’s 315,408 shares.
16 were reported by Royal Commercial Bank Of Canada. 342 are owned by Next Fincl Group. Wells Fargo And Mn invested in 6,500 shs or 0% of the stock. Morgan Stanley has invested 0% in Biomerica, Inc. (NASDAQ:BMRA). Perritt Capital Mgmt Incorporated holds 40,000 shs. Vanguard Gru Incorporated reported 16,641 shs. The North Carolina-based Natl Bank Of America De has invested 0% in Biomerica, Inc. (NASDAQ:BMRA). Tower Cap Ltd Llc (Trc) reported 48 shs. Blackrock, New York-based fund reported 19,126 shs.

Biomerica, Inc. (NASDAQ:BMRA)’s earnings report is awaited by WallStreet on April, 15, Zacks reports. earnings per share of $-0.05 is 25.00 % down from 2018’s $-0.04 EPS. Wall Street sees 0.00 % EPS growth as of April, 15. BMRA is hitting $2.51 during the last trading session, after increased 1.21%.Currently Biomerica, Inc. is downtrending after 36.95% change in last March 28, 2018. BMRA has 2,180 shares volume. BMRA underperformed by 41.32% the S&P 500.

Biomerica, Inc., together with its subsidiaries, develops, makes, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide.The firm is worth $23.41 million. The companyÂ’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; and to measure the level of specific hormones, antibodies, antigens, or other substances, which exist in the human body in extremely small concentrations.Last it reported negative earnings. It primarily focuses on products for gastrointestinal, food intolerances, diabetes, and esoteric tests.

For more Biomerica, Inc. (NASDAQ:BMRA) news released recently go to: Globenewswire.com, , Investingnews.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “Biomerica Announces Fiscal Year End 2018 Financial Results – GlobeNewswire” released on August 30, 2018, “The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial – Yahoo! Finance News” on December 21, 2018, “Study Shows Biomerica’s Product-led Diet is Successful | INN – Investing News Network” with a publish date: November 07, 2018, “Mexico’s COFEPRIS (Mexico’s equivalent of the FDA) approves Biomerica colorectal screening test to help identify the early warning signs of colorectal cancer – GlobeNewswire” and the last “Biomerica Extends Exclusive License Agreement with Celtis Pharm (Telcon Pharmaceuticals) to December 2019 – GlobeNewswire” with publication date: November 07, 2017.